Antibacterial activity of rhodomyrtone on Clostridium difficile vegetative cells and spores in vitro

Clostridium difficile infection (CDI) is the leading cause of nosocomial antibiotic-associated diarrhoea and colitis, and is associated with high mortality and soaring healthcare costs [1]. The recommended treatment of adults with severe CDI is oral vancomycin or oral fidaxomicin [2]. Oral vancomycin is also recommended for children with severe or fulminant CDI [2]. However, the rising incidence of CDI since 2000, together with the frequency of relapses and emergence of hypervirulent and antibiotic-resistant strains, has increased the urgency for new treatments [3,4].
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Source Type: research